Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Strategy Inc. (MSTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Strategy Inc. — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $300.09 (market cap $8.04B), while Strategy Inc. trades at $97.97 (market cap $35.38B). The key difference: Strategy Inc. is far larger — about 4.4× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Strategy Inc. nearer its low. Which is the better fit depends on your goals.
| BIO | MSTR | |
|---|---|---|
Market Cap | $8.04B | $35.38B |
Sector | Health | Technology |
52-Week High | $339.75 | $455.90 |
52-Week Low | $241.71 | $82.31 |
Enterprise Value | $7.85B | $50.42B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
MSTR trades at $92.10, down 2.68% on the day, reflecting bearish technical signals and volatile earnings. The stock shows a low P/E of 5.3 and P/B of 0.91, but negative profitability metrics like a net income margin of -2,482.01% highlight financial strain. Recent news indicates scrutiny over Bitcoin-related strategy shifts, with cash flow heavily influenced by financing activities.
Outlook remains cautious due to persistent losses and high debt, though analyst consensus is bullish with a $237.63 price target. Key risks include earnings volatility and reliance on financing; investors should weigh valuation against fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Strategy Inc.
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web
Read more on MSTR →
